Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer

Prostate

Volumn 73, Issue 6, 2013, Pages 596-604

  Wu, Ziqing ^a   He, Benfu ^b   He, Jincan ^a   Mao, Xiangming ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b 421th Hospital of PLA   (China)

Author keywords

miR 153; proliferation; prostate cancer; PTEN

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CYCLIN D1; LUCIFERASE; MICRORNA; MICRORNA 153; PROTEIN KINASE B; TRANSCRIPTION FACTOR FKHR; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; BIOLOGICAL FUNCTIONS; CANCER CELL; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; GENE EXPRESSION; GENETIC REGULATION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROSTATE CANCER; PTEN GENE; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; UPREGULATION;

3' UNTRANSLATED REGIONS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 84875807408     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22600     Document Type: Article

References (42)

1. Balmain A,. Cancer genetics: From Boveri and Mendel to microarrays. Nat Rev Cancer 2001; 1 (1): 77-82.
2. Hahn WC, Weinberg RA,. Modelling the molecular circuitry of cancer. Nat Rev Cancer 2002; 2 (5): 331-341.
3. Doerfler W, Hohlweg U, Müller K, Remus R, Heller H, Hertz J,. Foreign DNA integration-perturbations of the genome-oncogenesis. Ann N Y Acad Sci 2001; 945: 276-288.
4. Bartel DP,. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004; 116 (2): 281-297.
5. Ambros V,. The functions of animal microRNAs. Nature 2004; 431 (7006): 350-355.
6. Gregory RI, Shiekhattar R,. MicroRNA biogenesis and cancer. Cancer Res 2005; 65 (9): 3509-3512.
7. Calin GA, Croce CM,. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6 (11): 857-866.
8. Esquela-Kerscher A, Slack FJ,. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006; 6 (4): 259-269.
9. Ruvkun G,. Clarifications on miRNA and cancer. Science 2006; 311 (5757): 36-37.
10. Hsing AW, Tsao L, Devesa SS,. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000; 85 (1): 60-67.
11. Hsing AW, Chokkalingam AP,. Prostate cancer epidemiology. Front Biosci 2006; 11: 1388-1413.
12. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG,. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7 (4): 256-269.
13. Bianchi-Frias D, Pritchard C, Mecham BH, Coleman IM, Nelson PS,. Genetic background influences murine prostate gene expression: Implications for cancer phenotypes. Genome Biol 2007; 8 (6): R117.
14. Borley N, Feneley MR,. Prostate cancer: Diagnosis and staging. Asian J Androl 2009; 11 (1): 74-80.
15. Punnen S, Nam RK,. Indications and timing for prostate biopsy, diagnosis of early stage prostate cancer and its definitive treatment: A clinical conundrum in the PSA era. Surg Oncol 2009; 18 (3): 192-199.
16. Mihelich BL, Khramtsova EA, Arva N, Vaishnav A, Johnson DN, Giangreco AA, Martens-Uzunova E, Bagasra O, Kajdacsy-Balla A, Nonn L,. miR-183-96-182 cluster is overexpressed in prostate tissue and regulates zinc homeostasis in prostate cells. J Biol Chem 2011; 286 (52): 44503-44511.
17. Jalava SE, Urbanucci A, Latonen L, Waltering KK, Sahu B, Jänne OA, Seppälä J, Lähdesmäki H, Tammela TL, Visakorpi T,. Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer. Oncogene 2012; DOI: 10.1038/onc.2011.624.
18. Medema RH, Kops GJ, Bos JL, Burgering BM,. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 2000; 404 (6779): 782-787.
19. Kops GJ, Medema RH, Glassford J, Essers MA, Dijkers PF, Coffer PJ, Lam EW, Burgering BM,. Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. Mol Cell Biol 2002; 22 (7): 2025-2036.
20. Schmidt M, Fernandez de Mattos S, van der Horst A, Klompmaker R, Kops GJ, Lam EW, Burgering EW, Medema RH,. Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Mol Cell Biol 2002; 22 (22): 7842-7852.
21. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME,. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96 (6): 857-868.
22. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R,. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275 (5308): 1943-1947.
23. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV,. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997; 15 (4): 356-362.
24. Li DM, Sun H,. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 1997; 57 (11): 2124-2129.
25. Ali IU, Schriml LM, Dean M,. Mutational spectra of PTEN/MMAC1 gene: A tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst 1999; 91 (22): 1922-1932.
26. Pourmand G, Ziaee AA, Abedi AR, Mehrsai A, Alavi HA, Ahmadi A, Saadati HR,. Role of PTEN gene in progression of prostate cancer. Urol J 2007; 4 (2): 95-100.
27. Schmitz M, Grignard G, Margue C, Dippel W, Capesius C, Mossong J, Nathan M, Giacchi S, Scheiden R, Kieffer N,. Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis. Int J Cancer 2007; 120 (6): 1284-1292.
28. Franke TF, Kaplan DR, Cantley LC, Toker A,. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 1997; 275 (5300): 665-668.
29. Chen Q, Ganapathy S, Singh KP, Shankar S, Srivastava RK,. Resveratrol induces growth arrest and apoptosis through activation of FOXO transcription factors in prostate cancer cells. PLoS One 2010; 5 (12): e15288.
30. Zhang H, Pan Y, Zheng L, Choe C, Lindgren B, Jensen ED, Westendorf JJ, Cheng L, Huang H,. FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion. Cancer Res 2011; 71 (9): 3257-3267.
31. Di Cristofano A, De Acetis M, Koff A, Cordon-Cardo C, Pandolfi PP,. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 2001; 27 (2): 222-224.
32. Kim MJ, Cardiff RD, Desai N, Banach-Petrosky WA, Parsons R, Shen MM, Abate-Shen C,. Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci USA 2002; 99 (5): 2884-2889.
33. Abate-Shen C, Banach-Petrosky WA, Sun X, Economides KD, Desai N, Gregg JP, Borowsky AD, Cardiff RD, Shen MM,. Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res 2003; 63 (14): 3886-3890.
34. Backman SA, Ghazarian D, So K, Sanchez O, Wagner KU, Hennighausen L, Suzuki A, Tsao MS, Chapman WB, Stambolic V, Mak TW,. Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten. Proc Natl Acad Sci USA 2004; 101 (6): 1725-1730.
35. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, Khoo AS, Roy-Burman P, Greenberg NM, Van Dyke T, Cordon-Cardo C, Pandolfi PP,. Pten dose dictates cancer progression in the prostate. PLoS Biol 2003; 1 (3): E59.
36. Zhang BG, Li JF, Yu BQ, Zhu ZG, Liu BY, Yan M,. microRNA-21 promotes tumor proliferation and invasion in gastric cancer by targeting PTEN. Oncol Rep 2012; 27 (4): 1019-1026.
37. Tan G, Shi Y, Wu ZH,. MicroRNA-22 promotes cell survival upon UV radiation by repressing PTEN. Biochem Biophys Res Commun 2012; 417 (1): 546-551.
38. Kong G, Zhang J, Zhang S, Shan C, Ye L, Zhang X,. Upregulated microRNA-29a by hepatitis B virus X protein enhances hepatoma cell migration by targeting PTEN in cell culture model. PLoS One 2011; 6 (5): e19518.
39. Zhang C, Kang C, Wang P, Cao Y, Lv Z, Yu S, Wang G, Zhang A, Jia Z, Han L, Yang C, Ishiyama H, Teh BS, Xu B, Pu P,. MicroRNA-221 and -222 regulate radiation sensitivity by targeting the PTEN pathway. Int J Radiat Oncol Biol Phys 2011; 80 (1): 240-248.
40. Olive V, Bennett MJ, Walker JC, Ma C, Jiang I, Cordon-Cardo C, Li QJ, Lowe SW, Hannon GJ, He L,. miR-19 is a key oncogenic component of mir-17-92. Genes Dev 2009; 23 (24): 2839-2849.
41. Li G, Zhao J, Peng X, Liang J, Deng X, Chen Y,. The mechanism involved in the loss of PTEN expression in NSCLC tumor cells. Biochem Biophys Res Commun 2012; 418 (3): 547-552.
42. Tang ED, Nuñez G, Barr FG, Guan KL,. Negative regulation of the forkhead transcription factor FKHR by Akt. J Biol Chem 1999; 274 (24): 16741-16746.